CTNM (Contineum Therapeutics) Common Stock : $0.03 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Common Stock?

Contineum Therapeutics's quarterly common stock stayed the same from Jun. 2024 ($0.03 Mil) to Sep. 2024 ($0.03 Mil) and stayed the same from Sep. 2024 ($0.03 Mil) to Dec. 2024 ($0.03 Mil).

Contineum Therapeutics's annual common stock stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.03 Mil).

Contineum Therapeutics Common Stock Historical Data

The historical data trend for Contineum Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Common Stock Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Common Stock

0.01

0.03

Contineum Therapeutics Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial					-	-	0.03	0.03	0.03

Contineum Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Contineum Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

3565 General Atomics Court, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.